Edwards Lifesciences beats the Street in Q1 and increases sales outlook

Edwards Lifesciences (NYSE: EW) reported first-quarter results that exceeded Wall Street expectations after market close Thursday.

The maker of catheter-delivered heart implants — including transcatheter aortic valve replacement (TAVR) systems and transcatheter mitral and tricuspid therapies (TMTT) — also increased its full-year sales guidance. EW’s stock price was relatively flat in after-hours trading.